--- title: "08:01 ET CoreAge Rx Introduces Flat-Rate Pricing for GLP-1 Medications" type: "News" locale: "zh-CN" url: "https://longbridge.com/zh-CN/news/273376015.md" description: "CoreAge Rx, a telehealth pharmacy, has introduced a flat-rate pricing model for GLP-1 medications, including compounded semaglutide at $99/month and tirzepatide at $149/month when paid annually. This model aims to eliminate hidden fees and provide predictable costs for patients. All consultation fees, medications, and overnight shipping are included in a single annual payment, ensuring no surprises regardless of dosage changes. The telehealth service allows patients to manage their treatment online, with medications delivered within three to five business days. CoreAge Rx emphasizes accessibility and affordability in weight management solutions." datetime: "2026-01-22T13:02:09.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/273376015.md) - [en](https://longbridge.com/en/news/273376015.md) - [zh-HK](https://longbridge.com/zh-HK/news/273376015.md) --- > 支持的语言: [English](https://longbridge.com/en/news/273376015.md) | [繁體中文](https://longbridge.com/zh-HK/news/273376015.md) # 08:01 ET CoreAge Rx Introduces Flat-Rate Pricing for GLP-1 Medications , /PRNewswire/ -- CoreAge Rx, a telehealth pharmacy specializing in weight management solutions, today announced a pricing structure designed to eliminate hidden fees and provide predictable costs for patients seeking GLP-1 medications. The company now offers compounded semaglutide starting at $99 per month when paid annually and compounded tirzepatide at $149 per month when paid annually, with all dosage levels available at the same flat rate and no membership fees. The pricing model addresses a common challenge patients face when seeking weight loss treatment: unexpected costs and complex fee structures. CoreAge Rx's approach includes all consultation fees, medication, and overnight shipping in a single annual payment, with costs remaining consistent regardless of dosage increases throughout the year. "Many patients are frustrated by hidden fees, membership charges, and prices that change as their treatment progresses," said Ella Jones, spokesperson for CoreAge Rx. "Our transparent pricing model means patients know exactly what they'll pay from the start. Whether you're taking 2.5mg or 15mg of tirzepatide, the annual cost remains the same. No surprises." The company's streamlined process allows patients to complete a brief online consultation, receive doctor approval, and have medications delivered to their doorstep in as little as three to five business days. All consultations are reviewed by U.S.-licensed physicians who partner with 503A state board-regulated compounding pharmacies. CoreAge Rx's GLP-1 program includes both semaglutide and tirzepatide options. Semaglutide, which contains the same active ingredient as Ozempic and Wegovy, is associated with 15-20% weight loss in clinical studies. Tirzepatide, containing the same active ingredient as Mounjaro and Zepbound, works on two GLP receptors and is associated with 20-22% weight loss. The telehealth model eliminates the need for in-person doctor visits and allows patients to manage their treatment entirely online. Free overnight cold shipping is included with every order, and the company provides ongoing support through its customer service team. "Accessibility and affordability shouldn't be barriers to effective weight management," Jones added. "By offering predictable annual pricing and a fully online process, we're making it easier for patients to access these medications without navigating complex insurance requirements or unexpected costs." For more information about CoreAge Rx's pricing or to complete a free online consultation, visit https://www.coreagerx.com/. SOURCE CoreAge Rx ### 相关股票 - [Defiance Daily Target 2X Long LLY ETF (LLYX.US)](https://longbridge.com/zh-CN/quote/LLYX.US.md) - [iShares Global Healthcare (IXJ.US)](https://longbridge.com/zh-CN/quote/IXJ.US.md) - [ALPS Medical Breakthrough (SBIO.US)](https://longbridge.com/zh-CN/quote/SBIO.US.md) - [First Trust NYSE Arca Biotech Index Fd (FBT.US)](https://longbridge.com/zh-CN/quote/FBT.US.md) - [Proshares Ultra Nasdaq Biotech (BIB.US)](https://longbridge.com/zh-CN/quote/BIB.US.md) - [SPDR S&P Biotech (XBI.US)](https://longbridge.com/zh-CN/quote/XBI.US.md) - [iShares US Medical Devices (IHI.US)](https://longbridge.com/zh-CN/quote/IHI.US.md) - [Health Care Select Sector SPDR (XLV.US)](https://longbridge.com/zh-CN/quote/XLV.US.md) - [iShares US Pharma (IHE.US)](https://longbridge.com/zh-CN/quote/IHE.US.md) - [VanEck Biotech ETF (BBH.US)](https://longbridge.com/zh-CN/quote/BBH.US.md) - [Defiance Daily Target 2X Long NVO ETF (NVOX.US)](https://longbridge.com/zh-CN/quote/NVOX.US.md) - [Direxion Daily LLY Bull 2X Shares (ELIL.US)](https://longbridge.com/zh-CN/quote/ELIL.US.md) - [Novo Nordisk AS (NVO.US)](https://longbridge.com/zh-CN/quote/NVO.US.md) - [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/zh-CN/quote/IBB.US.md) - [Ark Genomic Revolution ETF (ARKG.US)](https://longbridge.com/zh-CN/quote/ARKG.US.md) - [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/zh-CN/quote/PBE.US.md) - [Eli Lilly (LLY.US)](https://longbridge.com/zh-CN/quote/LLY.US.md) - [Invesco Nasdaq Biotechnology ETF (IBBQ.US)](https://longbridge.com/zh-CN/quote/IBBQ.US.md) - [VG Health (VHT.US)](https://longbridge.com/zh-CN/quote/VHT.US.md) ## 相关资讯与研究 - [Novo Nordisk Launches Discounted Subscription Program for Wegovy Obesity Drugs -- Update](https://longbridge.com/zh-CN/news/281201382.md) - [NHS clears Wegovy to reduce risk of heart attack and stroke](https://longbridge.com/zh-CN/news/281323250.md) - [13:02 ETRO LAUNCHES ELI LILLY'S KWIKPEN®, OFFERING PATIENTS A MORE CONVENIENT WAY TO TAKE ZEPBOUND®](https://longbridge.com/zh-CN/news/281557703.md) - [InSilico Medicine Strikes Multi-Billion-Dollar AI Drug Discovery Deal With Eli Lilly](https://longbridge.com/zh-CN/news/280909399.md) - [BUZZ-Street View: Lilly's $7.8 billion Centessa buyout validates sleep‑drug market](https://longbridge.com/zh-CN/news/281367948.md)